key: cord-0723961-r7bi8erp
authors: Aldy, Kim; Cao, Dazhe James; Weaver, Mary Madison; Rao, Devika; Feng, Sing‐Yi
title: E‐cigarette or vaping product use‐associated lung injury (EVALI) features and recognition in the emergency department
date: 2020-06-08
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12112
sha: 788353e57a871701b1398f72523d00915fe35321
doc_id: 723961
cord_uid: r7bi8erp

Since August 2019, the pulmonary disease termed e‐cigarette or vaping product‐use associated lung injury (EVALI), has resulted in 2758 hospitalizations and 64 deaths in the United States. EVALI is considered in patients who have vaped or dabbed within 90 days of symptom onset, and have abnormal lung imaging in the absence of any pulmonary infection. The majority of EVALI patients are otherwise healthy adolescents and young adults. The leading etiology of EVALI is contamination of delta‐9‐tetrahydrocannabinoid (THC) e‐liquids with vitamin E acetate. Although the exact pathophysiology of vitamin E acetate‐induced lung injury is unknown, vitamin E acetate may lead to pulmonary lipid accumulation and/or interfere with surfactant functioning. EVALI symptoms are vague but consist of a constellation of constitutional, pulmonary, and gastrointestinal symptoms. Patients often present multiple times to healthcare facilities as their clinical condition worsens with a considerable mortality risk. The diagnosis of EVALI hinges on obtaining history leading to the recognition of vaping/dabbing. Physicians need to be persistent, but nonjudgmental, in obtaining vaping histories, especially in THC‐prohibited states. Radiographical findings of nonspecific bilateral ground‐glass infiltrates are best detected on computed tomography. Management for EVALI requires a multidisciplinary approach focused on supportive respiratory care and ruling‐out infectious causes. Corticosteroids may be of benefit. Most patients who are hypoxic, have comorbidities, or lack appropriate follow‐up within 24–48 hours should be admitted for monitoring. Patients may benefit from substance abuse counseling and should be instructed to avoid vaping. As the outbreak continues, cases should be reported to local health departments and poison control centers.

Vaping devices include e-cigarettes, vape pens, dab pens, and personal vaporizers, or so-called "mods" based on the ability to alter specifications and modify the smoking experience. All devices share a similar mechanism: a battery-powered heated coil vaporizes a liquid contained in a cartridge producing an aerosol, which is then inhaled through a mouthpiece. In contrast, dabbing aerosolizes a wax concentrate of cannabis by dabbing it onto a modified device consisting of a heated nail with an overlying dome attached to a water pipe that the user inhales through. 1 in nicotine content alone. 9 Lacking accountability and enforcement of e-liquid components has led to potential health risks secondary to constituents without long-term human inhalational safety data.

In August 2019, the first clusters of previously healthy patients with severe lung injury and a common association with e-cigarette use were recognized by clinicians in Wisconsin and Illinois. 10 

The CDC has implemented a case definition to help with their epidemiologic evaluation (Table 1) . Per these criteria, EVALI is suspected in patients with the presence of a pulmonary illness and abnormal lung imaging, in those who have a history of vaping or dabbing within 90 days of symptom onset and in the absence of known or suspected infectious etiology. Although 90 days was chosen for inclusion, patients in a recent case series reported vaping between 3 and 9 days prior to presentation. 13 with no lung injury. 18 The exact pathophysiologic mechanism linking vitamin E acetate to lung injury may stem from its inability to be absorbed by the pulmonary tissue leading to accumulation and interference with surfactant. 18 Although vitamin E acetate in THC containing cartridges is the prime suspected etiology for EVALI, 13% of EVALI patients endorsed exclusive vaping of nicotinecontaining cartridges or e-liquids. 15 At this point, the possibility of an alternative etiology or multiple implicating agents cannot be excluded.

As of January 2020, 76% of patients were <35 years old and 15% were <18 years old. 11 Males comprised 66% of hospitalized EVALI patients. 11 Young adults and adolescents are disproportionately affected by EVALI, which is likely a reflection of the age group that dominates e-cigarette use. 19 A majority of patients were white (73%), whereas 15% were Hispanic. 20 10 Creatinine elevation is infrequently seen but may occur due to prerenal causes, such as hypovolemia with dehydration.

By the CDC inclusion criteria for EVALI, all patients have abnormal radiographs; either chest x-ray or computed tomography (CT). Initial chest x-ray was abnormal and 94% of patients in 3 case series, with findings including nonspecific bilateral opacities or infiltrates. 10, 22, 23 The 6% with negative chest x-rays have positive findings on chest

CTs. The most frequent CT finding is bilateral diffuse and basilar ground glass opacities with subpleural sparing 24 (Figure 1 ). This nonspecific pattern is also suggestive of atypical pneumonia or diffuse alveolar hemorrhage. Patients presenting with predominant gastrointestinal symptoms may have incidental pulmonary findings on CT of abdomen/pelvis, especially because pulmonary findings are typically seen in the lower dependent lung fields. 25 In addition, CT is more sensitive for pneumothorax and/or pneumomediastinum, both of which have been reported in EVALI as illustrated by 2 recent case series where these were noted on CT in 18% and 10% of patients, respectively. 10,22 x-ray is normal. 21, [26] [27] [28] Chest CT with intravenous contrast may also be helpful in ruling out other causes of hypoxia, such as pulmonary embolism.

F I G U R E 1 EVALI chest x-ray and chest CT Imaging in an otherwise healthy adolescent

Determining need for hospital admission versus discharge requires careful clinical consideration by emergency physicians due to the high risk of rehospitalization and mortality among EVALI patients (Figure 2 ).

One out of every 7 EVALI deaths occurred in a median of 3 days after hospital discharge. 12 Patients potentially appropriate for outpatient management have normal oxygen saturations ≥95% with no respiratory distress on room air, lack high-risk comorbidities such as chronic obstructive pulmonary disease or congestive heart failure, and have a support system for outpatient follow-up. 28 Due to the considerable degree of rehospitalization and death, ensuring follow-up within 24-48 hours post-discharge is imperative. Briefly discussing with the primary care provider can help ensure close follow up. If a patient lacks adequate outpatient support systems for follow-up, the patient warrants admission due to the potential for rapid illness progression. 28 As expected, a higher incidence of chronic conditions (pulmonary, cardiac, advanced age, and diabetes) was present among patients who died post-discharge. 12 Discharge prescriptions may include a short course of oral corticosteroids with education on pharmacological tapering and antibiotic/antiviral prescriptions if warranted. 28 The dosage and course may vary depending on clinical severity, and the decision may be in conjunction with pulmonary specialists. Glucocorticoids recommended by other institutions 10, 22, 23 have been shown to improve disease severity and are a treatment modality consistent with standard management of steroid-responsive pulmonary disease practiced by lung specialists. Education on strict return-to-ED warnings, annual influenza vaccination, and access to outpatient cessation and addiction resources should also be provided. 21, 28 If the patient intends to continue vaping, the patient should be instructed to avoid THC, illicit substances, and mixing or cutting substances. 21 Patients who smoke nicotine e-cigarettes should not switch to smoking traditional combustible cigarettes. In patients under 18 years of age, the CDC recommends that patients discontinue vaping altogether.

For EVALI patients presenting with abnormal vital signs that require admission, emergency physicians serve as the first line for gathering an adequate vaping history and should present this new differential diag-nosis for consideration to the admitting team. EVALI patients benefit from consultation with pulmonology, medical toxicology (or local poison center), and/or psychiatry who may recommend further specific testing and evaluation once the patient is admitted. 22 Intravenous or oral steroids are anecdotally beneficial in hospitalized EVALI patients.

Recommended doses for admitted patients ranges from methylprednisone 120-500 mg daily 29 or 1 mg/kg for 1-2 days with a transition to oral prednisone. 22 Admission to the medical floor versus critical care area should be determined by the severity of presenting symptoms and need for noninvasive or invasive respiratory support. Pneumothorax and/or pneumomediastinum are reported in EVALI 10, 22 and may worsen with escalation of positive pressure ventilation. Extracorporeal membrane oxygenation has been successful in EVALI and is recommended for patients that are continually hypoxic after standard ventilation management.

Probable or confirmed EVALI cases are reportable to both poison control and the local health department. Because EVALI is a diagnosis of exclusion, reporting may not be feasible at the time of the patient's initial presentation to the ED. Therefore, in a patient with concern for EVALI, the emergency physician should report the occurrence to the poison control center to initiate longitudinal follow-up and aid in monitoring by the local health department.

Assessment of e-cigarette use during a social history evaluation for any patients presenting with a constellation of respiratory, gastrointestinal, and/or constitutional symptoms is paramount. Triage screening by nonphysician staff may capture use. If the technology allows, consider integration of e-cigarette/vaping history into the electronic medical record system.

Emergency physicians should promptly recognize the risk factors and presentation patterns in EVALI patients. Imaging findings of EVALI may be overlooked due to unfamiliarity of this diagnosis by radiologists.

In addition, a thorough vaping history may be difficult to elicit and may require numerous attempts, especially when patients exhibit more severe symptoms. With rapid recognition and diagnosis of EVALI by the multi-disciplinary team, the morbidity and mortality of EVALI can hopefully be mitigated. Further investigation of this phenomenon continues to be warranted.

KA takes responsibility of the paper as a whole.

Beyond the bud: Emerging methods of cannabis consumption for youth

Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols

E-cigarettes as a source of toxic and potentially carcinogenic metals

Endotoxin and [Formula: see text] contamination in electronic cigarette products sold in the United States

Self-reported reasons for vaping among 8th, 10th, and 12th graders in the US: Nationally-representative results

Harm perceptions of intermittent tobacco product use among U.S. youth

The impact of cannabis access laws on opioid prescribing

United States Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products

The nicotine content of a sample of E-cigarette liquid manufactured in the United States

Pulmonary illness related to Ecigarette use in illinois and Wisconsin -Final report

Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping

Characteristics of patients experiencing rehospitalization or death after hospital discharge in a nationwide outbreak of E-cigarette, or vaping, product useassociated lung injury -United States

Vaping-associated acute lung injury: A case series

Risk factors for E-cigarette, or vaping, product use-associated lung injury (EVALI) among adults who use E-cigarette, or vaping, products -illinois

Update: Demographic, product, and substance-use characteristics of hospitalized patients in a nationwide outbreak of E-cigarette, or vaping, product-use-associated lung injuries -United States

Characteristics of E-cigarette, or vaping, products used by patients with associated lung injury and products seized by law enforcement -Minnesota

Analysis of cannabinoid-containing fluids in illicit vaping cartridges recovered from pulmonary injury patients: Identification of vitamin E acetate as a major diluent

Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI

Department of Health and Human Services CfDCaP, National Center for Chronic Disease Prevention and Health Promotion

Update: Characteristics of a nationwide outbreak of E-cigarette, or vaping, product useassociated lung injury -United States

Update: Interim Guidance for health care providers for managing patients with suspected Ecigarette, or vaping, product use-associated lung injury -United States

Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: A prospective observational cohort study

E-cigarette, or vaping, product use associated lung injury (EVALI): Case series and diagnostic approach

Imaging Findings of Vaping-Associated Lung Injury

Ecigarette, or vaping, product use-associated lung injury in adolescents: A review of imaging features

Severe pulmonary disease associated with electronic-cigarette-product use -Interim guidance

Update: Interim guidance for health care providers evaluating and caring for patients with suspected E-cigarette, or vaping, product use associated lung injury -United States

Update: Interim guidance for health care professionals evaluating and caring for patients with suspected E-cigarette, or vaping, product use-associated lung injury and for reducing the risk for rehospitalization and death following hospital discharge -United States

Outbreak of electroniccigarette-associated acute lipoid pneumonia -North Carolina

E-cigarette or vaping product use-associated lung injury (EVALI) features and recognition in the emergency department

The authors declare no conflict of interest.

Kim Aldy DO, MBA https://orcid.org/0000-0002-3198-2321